Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research6

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research6

FiltersClear all

Status

Recruiting6
Not yet recruiting1
Active, not recruiting3
Completed3
Terminated1

Study type

Interventional5
Observational1

Phase

Phase 22
Not applicable2
Phase 41
Not reported1

Investigator

Catherine Riffin1
Anthony O. Ahmed1
Dimitris N Kiosses1
Miran W Salgado1
Parag Goyal1

Department

Medicine2
Psychiatry2
Neurology1
Radiology1

Condition

Cognitive Dysfunction6
Breast Neoplasms16
Crohn Disease13
Prostatic Neoplasms12
Leukemia, Myeloid, Acute11

Intervention type

Drug3
Behavioral2
Device1
Other1

Sponsor type

WCM (investigator-initiated)3
Other academic2
Industry1

Start date

Recruiting×Cognitive Dysfunction×Clear all

Showing 1–6 of 6 studiesSort:

RecruitingInterventional · Phase 4NCT04262206 ↗
PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults (PREVENTABLE)

FiltersClear all

Status

Recruiting6
Not yet recruiting1
Active, not recruiting3
Completed3
Terminated1

Study type

Interventional5
Observational1

Phase

Phase 22
Not applicable2
Phase 41
Not reported1

Investigator

Catherine Riffin1
Anthony O. Ahmed1
Dimitris N Kiosses1
Miran W Salgado1
Parag Goyal1

Department

Medicine2
Psychiatry2
Neurology1
Radiology1

Condition

Cognitive Dysfunction6
Breast Neoplasms16
Crohn Disease13
Prostatic Neoplasms12
Leukemia, Myeloid, Acute11

Intervention type

Drug3
Behavioral2
Device1
Other1

Sponsor type

WCM (investigator-initiated)3
Other academic2
Industry1

Start date

Recruiting×Cognitive Dysfunction×Clear all

Showing 1–6 of 6 studiesSort:

RecruitingInterventional · Phase 4NCT04262206 ↗
PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults (PREVENTABLE)

Show all 7

Show fewer

Sonja Blum1
Tracy A. Butler1

Show all 50

Show fewer

Heart Failure10
Depression9
Hematologic Neoplasms9
Neoplasms9
Obesity9
Atrial Fibrillation8
Burkitt Lymphoma8
Colitis, Ulcerative8
Multiple Myeloma8
Carcinoma, Non-Small-Cell Lung7
Leukemia7
Lymphoma, Non-Hodgkin7
Parkinson Disease7
Recurrence7
Cardiovascular Diseases6
Colorectal Neoplasms6
Inflammatory Bowel Diseases6
Lung Neoplasms6
Overweight6
Adenocarcinoma Of Esophagus5
Anxiety Disorders5
Coronary Artery Disease5
Depressive Disorder, Major5
Fibrosis5
Ischemic Stroke5
Lymphoma5
Lymphoma, Mantle-Cell5
Melanoma5
Pain5
Stroke5
Alzheimer Disease4
Cardiomyopathies4
Dementia4
Leukemia, Lymphocytic, Chronic, B-Cell4
Lung Diseases, Interstitial4
Lymphoma, Follicular4
Lymphoma, Large B-Cell, Diffuse4
Myelodysplastic Syndromes4
Agnosia3
Anemia, Sickle Cell3
Cerebral Hemorrhage3
Chronic Limb-Threatening Ischemia3
Depressive Disorder, Treatment-Resistant3
Diabetes Mellitus3
Diabetes Mellitus, Type 23

Parag GoyalPI

Intervention: Drug: Atorvastatin 40 Mg Oral Tablet · Drug: Placebo oral tablet
Dates: Sep 2020 – Dec 2026 (est.)
Sponsor: Duke University

Cognitive Impairment, MildDementiaCardiovascular Diseases

RecruitingInterventional · Not applicableNCT05081596 ↗

PATH-Pain: A Primary Care-Based Psychosocial Intervention To Improve Cognitive and Depression Outcomes in Older Adults With MCI and Early Stage AD

Dimitris N KiossesPI

Intervention: Behavioral: PATH-Pain
Dates: Jun 2022 – Jul 2027 (est.)
Sponsor: Weill Medical College of Cornell University

DepressionPainCognitive Impairment

RecruitingInterventional · Not applicableNCT06168604 ↗

The Pain Identification and Communication Toolkit: A Training Program to Support Family Caregivers of Persons With ADRD

Catherine RiffinPI

Intervention: Behavioral: Pain Identification and Communication Toolkit · Behavioral: Health Promotion Program
Dates: Dec 2023 – Oct 2027 (est.)
Sponsor: Weill Medical College of Cornell University

Caregiver BurdenCognitive ImpairmentDementia+2 more

RecruitingObservationalNCT06170268 ↗

Alzheimer's National Registry for Treatment and Diagnostics

Miran W SalgadoPISonja BlumPI

Intervention: Other: Routine Care Documentation
Dates: Oct 2022 – Dec 2032 (est.)
Sponsor: Alzheimer's Association National Office

Alzheimer Disease

RecruitingInterventional · Phase 2NCT06502964 ↗

Double-Blind, Placebo-Controlled Study of ALTO-101 in Patients With Schizophrenia and Cognitive Impairment

Anthony O. AhmedPI

Intervention: Drug: ALTO-101 · Device: ALTO-101 Transdermal Delivery System · Drug: Placebo · Device: Placebo Transdermal Delivery System
Dates: Jun 2024 – Feb 2026 (est.)
Sponsor: Alto Neuroscience

SchizophreniaCognitive Impairment

RecruitingInterventional · Phase 2NCT07553338 ↗

Safety Assessment of Leronlimab and Its Effect on Neuroinflammation Targets in Alzheimer's Disease

Tracy A. ButlerPI

Intervention: Drug: Leronlimab (700mg)
Dates: Apr 2026 – Nov 2027 (est.)
Sponsor: Weill Medical College of Cornell University

Mild Cognitive Impairment (MCI) Due to Alzheimer's DiseaseAlzheimer's Disease

Browse

Browse

PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults (PREVENTABLE)

PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults (PREVENTABLE)

PATH-Pain: A Primary Care-Based Psychosocial Intervention To Improve Cognitive and Depression Outcomes in Older Adults With MCI and Early Stage AD

The Pain Identification and Communication Toolkit: A Training Program to Support Family Caregivers of Persons With ADRD

Alzheimer's National Registry for Treatment and Diagnostics

Double-Blind, Placebo-Controlled Study of ALTO-101 in Patients With Schizophrenia and Cognitive Impairment

Safety Assessment of Leronlimab and Its Effect on Neuroinflammation Targets in Alzheimer's Disease